Premium
EPA + DHA supplementation reduces PMN activation in microenvironment of chronic venous leg ulcers: A randomized, double‐blind, controlled study
Author(s) -
McDaniel Jodi C.,
Szalacha Laura,
Sales Michelle,
Roy Sashwati,
Chafee Scott,
Parinandi Narasimham
Publication year - 2017
Publication title -
wound repair and regeneration
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.847
H-Index - 109
eISSN - 1524-475X
pISSN - 1067-1927
DOI - 10.1111/wrr.12558
Subject(s) - docosahexaenoic acid , elastase , eicosapentaenoic acid , medicine , proteases , inflammation , matrix metalloproteinase , gastroenterology , randomized controlled trial , wound healing , neutrophil elastase , polyunsaturated fatty acid , placebo , immunology , pharmacology , chemistry , pathology , fatty acid , biochemistry , enzyme , alternative medicine
Abstract Sustained high levels of activated polymorphonuclear leukocytes (PMNs) and PMN‐derived proteases in the microenvironment of chronic venous leg ulcers (CVLUs) are linked to chronic inflammation and delayed healing. Uncontrolled PMN activity eventually destroys newly developed tissue and degrades critical growth factors. The bioactive components of fish oil (n‐3 eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) have strong inflammation‐resolving actions and have been shown to assuage PMN activity, but have not been tested in CVLU patients. This randomized controlled study compared the effectiveness of oral EPA + DHA therapy to a placebo for reducing PMN activation in CVLU microenvironments. At Days 0, 28, and 56, markers of PMNs (CD15) and activated PMNs (CD66b), and levels of PMN‐derived proteases human neutrophil elastase and matrix metalloproteinase‐8 were measured in CVLU fluid from patients receiving standard compression therapy and (1) EPA + DHA therapy ( n = 16) or (2) placebo ( n = 19). By Day 56, the EPA + DHA Group had a significantly lower percentage of CD66b+ cells in CVLU fluid compared to Day 0 ( p = 0.02) and to Day 28 ( p = 0.05). Importantly, there were downward trends in levels of both matrix metalloproteinase‐8 and human neutrophil elastase over time in the EPA + DHA Group, which also demonstrated greater reductions in wound area by Day 28 (57% reduction) and Day 56 (76% reduction) than the Control Group (35% and 59%, respectively). Moreover, reductions in wound area had significant negative relationships with CD15+ cells in wound fluid at Days 28 ( p = 0.008) and 56 ( p < 0.001), and CD66b+ cells at Days 28 ( p = 0.04) and 56 ( p = 0.009). The collective findings provide supplemental evidence that high levels of activated PMNs in CVLU microenvironments inhibit healing, and suggest that EPA + DHA oral therapy may modulate PMN activity and facilitate healing of CVLUs when added to standard care regimens.